Vimarsana
Biggest News Aggregation in the World

B Program Dec News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from B Program Dec. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In B Program Dec Today - Breaking & Trending Today

HRSA ADR Panel Dismisses NACHC's 340B Complaint Against Two Drug Manufacturers - Healthcare - Vimarsana News

HRSA ADR Panel Dismisses NACHC's 340B Complaint Against Two Drug Manufacturers - Healthcare

He 340B program requires drug manufacturers to offer outpatient pharmaceuticals to statutorily defined covered entities (including certain hospitals and certain federal...

Source: mondaq.com
Third Circuit Denies 340B Program Contract Pharmacy Arrangements - Vimarsana News

Third Circuit Denies 340B Program Contract Pharmacy Arrangements

Wednesday, July 7, 2021 Recent court decisions and the subsequent rescission of a key advisory opinion have left the status of contract pharmacy programs in continued flux. On 30 December 2020, the Department of Health and Human Services (HHS) released Advisory Opinion 20-06 (the Advisory Opinion) stating that drug manufacturers are required to deliver drugs to contract pharmacies and charge no more than the 340B ceiling price. On 16 June 2021, the U.S. District Court for the District of Delaware issued a Memorandum Opinion (Decision) in  AstraZeneca Pharmaceuticals LP v. Becerra, ...

340B Update: HRSA Issues Final Warning Letter to Pharmaceutical Manufacturers That Their Contract Pharmacy Actions Violate 340B Statute | K&L Gates LLP - Vimarsana News

340B Update: HRSA Issues Final Warning Letter to Pharmaceutical Manufacturers That Their Contract Pharmacy Actions Violate 340B Statute | K&L Gates LLP

To embed, copy and paste the code into your website or blog: On 17 May 2021, the Acting Administrator of the Health Resources and Services Administration (HRSA), Diana Espinosa, sent letters to six pharmaceutical manufacturers stating that the manufacturers’ actions to limit access to 340B Program pricing for covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in direct violation of the 340B statute. 1 The letters order the manufacturers to immediately begin offering 340B pricing to covered entities through their contract pharmacy arra...

HRSA Issues Warning Letter to Pharma Companies on 340B Program Pricing - Vimarsana News

HRSA Issues Warning Letter to Pharma Companies on 340B Program Pricing

Advertisement 340B Update: HRSA Issues Final Warning Letter to Pharmaceutical Manufacturers that Their Contract Pharmacy Actions Violate 340B Statute Wednesday, May 26, 2021 On 17 May 2021, the Acting Administrator of the Health Resources and Services Administration (HRSA), Diana Espinosa, sent letters to six pharmaceutical manufacturers stating that the manufacturers’ actions to limit access to 340B Program pricing for covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in direct violation of the 340B statute. 1 The letters...